LYNKUET Drug Patent Profile

Name: LYNKUET Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Lynkuet patents expire, and when can generic versions of Lynkuet launch?

Lynkuet is a drug marketed by Bayer Hlthcare and is included in one NDA. There are six patents protecting this drug.

The generic ingredient in LYNKUET is elinzanetant. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the elinzanetant profile page.

DrugPatentWatch^® Generic Entry Outlook for Lynkuet

Lynkuet will be eligible for patent challenges on October 24, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 24, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for LYNKUET?
What are the global sales for LYNKUET?
What is Average Wholesale Price for LYNKUET?

Summary for LYNKUET

US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for LYNKUET
What excipients (inactive ingredients) are in LYNKUET?	LYNKUET excipients list
DailyMed Link:	LYNKUET at DailyMed

Drug patent expirations by year for LYNKUET

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LYNKUET

Generic Entry Date for LYNKUET^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY NDA: 219469 Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for LYNKUET

LYNKUET is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LYNKUET is ⤷ Start Trial.

This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	12,264,164	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	12,533,358	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	11,787,820	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	10,195,205	⤷ Start Trial				⤷ Start Trial
Bayer Hlthcare	LYNKUET	elinzanetant	CAPSULE;ORAL	219469-001	Oct 24, 2025		RX	Yes	Yes	10,774,091	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LYNKUET

See the table below for patents covering LYNKUET around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2016264034		⤷ Start Trial
Australia	2020201074		⤷ Start Trial
Brazil	112017024852		⤷ Start Trial
Canada	2984591		⤷ Start Trial
China	107635557		⤷ Start Trial
China	114272242		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for LYNKUET

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3297631	PA2026506	Lithuania	⤷ Start Trial	PRODUCT NAME: ELINZANETANT; REGISTRATION NO/DATE: EU/1/25/1991 20251117
3297631	C20260003	Finland	⤷ Start Trial
3297631	CR 2026 00007	Denmark	⤷ Start Trial	PRODUCT NAME: ELINZANETANT; REG. NO/DATE: EU/1/25/1991 20251118
3297631	LUC50035	Luxembourg	⤷ Start Trial	PRODUCT NAME: ELINZANETANT; AUTHORISATION NUMBER AND DATE: EU/1/25/1991 20251118
3297631	122026000009	Germany	⤷ Start Trial	PRODUCT NAME: ELINZANETANT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; AUTHORISATION NO/DATE: EU/1/25/1991 20251117
3297631	202640004	Slovenia	⤷ Start Trial	PRODUCT NAME: ELINZANETANT; NATIONAL AUTHORISATION NUMBER: EU/1/25/1991; DATE OF NATIONAL AUTHORISATION: 20251117; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

DrugChatter Q&A for LYNKUET

How much does lynkuet in adults cost per month?